Cosibelimab is under clinical development by Checkpoint Therapeutics and currently in Pre-Registration for Squamous Cell Carcinoma. According to GlobalData, Pre-Registration drugs for Squamous Cell Carcinoma have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Cosibelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cosibelimab is under development for the treatment of hematological malignancies and solid tumor including endometrial cancer, colorectal cancer, small-cell lung cancer, malignant pleural mesothelioma, head and neck cancer, advanced cutaneous squamous cell carcinoma, metastatic melanoma, metastatic Merkel cell carcinoma, renal cell carcinoma and metastatic transitional carcinoma of the urothelium. It is administered by intravenous route. The drug candidate is a fully humanized antibody which acts by targeting PD-L1.
It was also under development for the treatment of relapsed and refractory B-cell non-Hodgkin lymphoma, metastatic non-small cell lung cancer, metastatic non-squamous non-small cell lung cancer, blood cancer, hodgkin lymphoma (B-cell hodgkin lymphoma), relapsed and refractory chronic lymphocytic leukemia (CLL).
Checkpoint Therapeutics overview
Checkpoint Therapeutics, a subsidiary of Fortress Biotech Inc, is a clinical-stage biopharmaceutical company that acquires, develops, and commercializes novel treatments for solid tumor cancers. Its lead product candidate, CK-101 molecule is in Phase I clinical trials for the treatment of patients with positive epidermal growth factor receptor (EGFR). The company’s other lead product candidate CK-301, is an anti-PD L1 antibody intended for the treatment of patients with non-small cell lung cancer (NSCLC) and other solid tumors. Checkpoint Therapeutics’ other pipeline products include a portfolio of human immuno-oncology agents and targeted anti-cancer agents intended for the treatment of multiple types of cancer including renal cell carcinoma, EGFR mutation-positive NSCLC and multiple forms of cancer. The company also works in partnership with other pharmaceutical companies to co-develop its antibodies. Checkpoint Therapeutics is headquartered in New York, the US.
For a complete picture of Cosibelimab’s drug-specific PTSR and LoA scores, buy the report here.